Murdoch University Research Repository

Welcome to the Murdoch University Research Repository

The Murdoch University Research Repository is an open access digital collection of research
created by Murdoch University staff, researchers and postgraduate students.

Learn more

Enhancing immunity against melanoma using Type I interferon

Zemek, Rachael (2013) Enhancing immunity against melanoma using Type I interferon. Honours thesis, Murdoch University.

PDF - Front Pages
Download (650kB)
PDF - Whole Thesis
Download (5MB)


Melanoma is an aggressive cancer, which when diagnosed in the late stages has a median survival rate of 6 months. The current gold-standard for adjuvant therapy is high doses of the type I interferon (IFN)-2, which prolongs disease free survival, but not overall survival. This high-dose therapy has many serious side-effects, resulting in doses to be lowered to sub-therapeutic levels. It is not clear how IFN-2 acts to treat melanoma, however it is accepted that immune enhancement is involved. The two main type I IFN families, IFN- and IFN-, signal via the same receptor, however they have been found to be functionally different. Of the IFN- family, 13 subtypes have been discovered and there is evidence that each is functionally unique. This project explores the therapeutic efficacy of seven type I IFN subtypes, including IFN-2 and IFN-, in treating melanoma. To test efficacy, a model of DNA therapy to administer plasmids encoding the IFN subtypes was combined with a melanoma model utilizing B16 F1 cells expressing the immunogenic peptide glycoprotein B. We have found that the IFN- subtypes tested have greater efficacy than IFN-2 in treating melanoma. The IFN subtypes delayed tumour onset, and one subtype demonstrated a significant increase in survival time. In addition, therapeutic effects could be seen when sera levels were lower than that of IFN-2. The in vitro effects of the IFN subtypes on melanoma cells was examined, uncovering differences in potency. Furthermore, we have found evidence of anti-tumour immune enhancement is associated with IFN- therapy but not IFN-. This research shows that the IFN- subtypes differ in their anti-tumour efficacy, and potency of actions. Therefore the IFN- subtypes show potential as a superior therapy in treating melanoma, which may be administered at lower, less toxic doses.

Item Type: Thesis (Honours)
Murdoch Affiliation(s): School of Veterinary and Life Sciences
Supervisor(s): Waithman, J. and Fear, V.
Item Control Page Item Control Page


Downloads per month over past year